EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting KRAS Sensitizes Ferroptosis by Coordinately Regulating the TCA Cycle and Nrf2‐SLC7A11‐GPX4 Signaling in Hepatocellular Carcinoma

Jiaxin Zhang, Zuojia Liu iD, Wenjing Zhao, Chang Li, Fei Liu, Jin Wang

Smart Medicine · 2025-06 · 4 (2)

DOI: 10.1002/smmd.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Smart Medicine, online erschienen am 06.05.2025. Verfasst von Jiaxin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Sciences Changchun Institute of Applied Chemistry Changchun China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic KRAS, a notorious driver of cancer progression, remains a therapeutic challenge. In hepatocellular carcinoma (HCC), KRAS overexpression correlates with tumor aggressiveness. Here, we demonstrate that NSC48160 induces HCC cell death by suppressing KRAS expression. Metabolomic profiling revealed that NSC48160 significantly enhances intracellular tricarboxylic acid (TCA) cycle activity and fructose metabolism, disrupting redox homeostasis, and triggering ferroptosis. Combining NSC48160 with the SLC7A11 inhibitor HG106 synergistically eliminated HCC cells in vitro and suppressed tumor growth in vivo. Mechanistically, NSC48160 indirectly inhibits the Nrf2‐SLC7A11‐GPX4 axis, as evidenced by ferroptosis‐pathway array assays. Specifically, NSC48160 downregulates Nrf2 expression, thereby suppressing its downstream targets GPX4 and SLC7A11, ultimately promoting ferroptosis. Our findings establish NSC48160 as a novel KRAS inhibitor that induces ferroptosis through metabolic and redox reprogramming, offering a promising therapeutic strategy for KRAS‐driven HCC.

Schlagwörter

Stichwörter der Autor:innen

KRASNSC48160ferroptosishepatocellular carcinomametabolomics

Autor:innen und Institutionen

  • State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Sciences Changchun Institute of Applied Chemistry Changchun China.
  • School of Chinese Medicine Hong Kong Traditional Chinese Medicine Phenome Research Center Hong Kong Baptist University Hong Kong China.
  • Hepatobiliary Hospital of Jilin Province Changchun China.
  • Center for Theoretical Interdisciplinary Sciences Wenzhou Institute University of Chinese Academy of Sciences Wenzhou China.
  • Department of Chemistry and Physics Stony Brook University Stony Brook New York USA.

ORCID-Profile: Zuojia Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Liu, Z., Zhao, W., Li, C., Liu, F., & Wang, J. (2025). Targeting KRAS Sensitizes Ferroptosis by Coordinately Regulating the TCA Cycle and Nrf2‐SLC7A11‐GPX4 Signaling in Hepatocellular Carcinoma. Smart Medicine, 4(2). https://doi.org/10.1002/smmd.70005

Vancouver

Zhang J, Liu Z, Zhao W, Li C, Liu F, Wang J. Targeting KRAS Sensitizes Ferroptosis by Coordinately Regulating the TCA Cycle and Nrf2‐SLC7A11‐GPX4 Signaling in Hepatocellular Carcinoma. Smart Medicine. 2025;4(2). doi:10.1002/smmd.70005

BibTeX
@article{Zhang2025,
  author = {Zhang, Jiaxin and Liu, Zuojia and Zhao, Wenjing and Li, Chang and Liu, Fei and Wang, Jin},
  title = {Targeting KRAS Sensitizes Ferroptosis by Coordinately Regulating the TCA Cycle and Nrf2‐SLC7A11‐GPX4 Signaling in Hepatocellular Carcinoma},
  journal = {Smart Medicine},
  year = {2025},
  volume = {4},
  number = {2},
  doi = {10.1002/smmd.70005}
}
Kostenlos starten →